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failure (CHF) (NYHA III-IV, EF 35%) prompted us to
perform the present analysis. OBJECTIVE: Cost-effec-
tiveness analysis of E versus placebo in conjunction with
standard treatment, in the management of CHF in Po-
land. METHODS: SOLVD results are used to estimate
the increase in survival and the reduction in the number
of hospitalizations arising from the use of E in CHF man-
agement. Life-years saved are estimated on the basis of
original patient data from SOLVD, using survival curve
analysis. Direct medical costs are estimated on the basis
of current treatment patterns in Poland. The perspective
of the health care payers and a time frame of four years
was taken. The decision model was used to quantitate
risk benefits, and costs of alternative treatment. One-way
and multi-way sensitivity Monte Carlo analysis was per-
formed. RESULTS: E increases mean survival by 1.88
months/patient/4 years and is cost saving, reducing direct
medical costs for CHF patient (330 zl  $80.5/4 years).
Sensitivity analysis indicated that therapy with E re-
mained cost saving even when drug cost was increased
two times and the risk of hospitalization in the E group
increased by 20%. When three variables (frequency, hos-
pitalization cost, life-years saved) were changed simulta-
neously, in 77.2% simulations ICER value was negative,
and 90% were in range (16 863/5 587 PLN). CON-
CLUSION: The addition of E to conventional CHF man-
agement in Poland should improve survival and may pro-
vide a net reduction in treatment costs. There are 100,000
hospitalizations/year attributable to CHF in Poland.
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OBJECTIVE: To estimate the annual direct cost of treat-
ment of side effects of antiarrhythmic drugs (AAD) in pa-
tients with atrial fibrillation or flutter (AF/F) using physi-
cian interview data. METHODS: A Markov model with
the periodicity of one month was used. Patients were fol-
lowed for one year. The primary measure of interest was
the weighted average cost of treatment of side effects at
one year following therapy initiation. Transition proba-
bilities (i.e., incidence of side effects, recurrence, stroke,
and death) and medical care utilization were obtained
from an expert panel of 15 practicing cardiologists in the
USA. Unit costs were estimated from published and unpub-
lished sources. The cost for each therapy was estimated for
patients with and without structural heart disease, then
weighted by corresponding estimates of prescription fre-
quencies to obtain the weighted average cost of treatment
of side effects for a typical AF/F patient. RESULTS: The
annual direct cost of treatment of side effects of AAD
was US $1,198 (ranged from $1,356 to $1,115) for a
typical AF/F patient. Inpatient and outpatient costs were
$1,165 (ranged from $1,326 to $1,092) and $33 (ranged
from $46 to $18), respectively. Treatment costs of proar-
rhythmia, bradycardia, hypotension, and depressed ven-
tricular function were $541 (ranged from $750 to $437),
$336 (ranged from $451 to $116), $124 (ranged from
$190 to $106), and $58 (ranged from $124 to $33), re-
spectively. The treatment costs of other side effects, such
as thrombocytopenia and gastrointestinal upset, also
were substantial. CONCLUSIONS: As perceived by
practicing cardiologists in the USA, the direct medical
treatment costs of side effects of AAD in AF/F patients are
substantial. Proarrhythmia, bradycardia, and hypoten-
sion are perceived to be the most costly side effects of
AAD.
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Selective estrogen receptor modulators (SERMs) are gen-
erally believed to be effective in treating breast cancer
and in the case of raloxifene improving bone mineral
density in postmenopausal women. Since these agents
also have a beneficial effect on lipid profile, it has been
argued that reductions in coronary heart disease (CHD)
risk—and hence cost savings—associated with their use
may be significant. The potential magnitude of these ben-
efits, however, is not known. OBJECTIVE: To determine
whether the lipid effects of SERMs translate into mean-
ingful clinical and economic benefits. METHODS: We
developed a decision-analytic model of CHD treatment
and prevention to estimate the benefits (reductions in oc-
currences of initial CHD events relative to no therapy
and associated cost savings) of lipid modification associ-
ated with use of raloxifene and tamoxifen. Probabilities
of CHD event occurrence were estimated using a multi-
variate coronary risk appraisal equation developed using
Framingham Heart Study data. Mean values of serum
lipids and other risk factors were obtained from national
survey data, while the lipid effects of SERM therapy and
costs of CHD treatment were obtained from published
literature. RESULTS: In a hypothetical cohort of 50 year
old postmenopausal women currently free of CHD, use
of raloxifene and tamoxifen was associated with 8% and
14% reductions in the occurrence of initial CHD events
over 10 years relative to no therapy, and associated sav-
ings in per capita costs of CHD treatment of $9 and $15,
respectively. CONCLUSION: Improvements in coro-
nary risk profiles and savings in costs of CHD treatment
associated with use of SERMs provide only a modest in-
crement to the other benefits of these agents.
